Krsnaa Diagnostics Ltd. Share Price

’s Dual-Engine Growth: PPP and Retail Expansion

is actively driving its next phase of corporate growth through a clearly defined two-pronged business model. This strategy balances institutional collaborations with direct-to-consumer market expansion to secure long-term value. Solidifying Public-Private Partnership (PPP) Leadership: A cornerstone of the company’s operational blueprint is its dominant position in the PPP segment. By partnering with government healthcare frameworks and public hospitals, Krsnaa establishes large-scale, deeply integrated diagnostic centers that capture high-volume patient inflows. Aggressive Retail Touchpoint Expansion: Complementing its institutional framework, the company is rapidly scaling its independent retail footprint. This expansion targets private consumers directly, diversifying revenue streams away from purely public tenders and enhancing overall brand equity in competitive diagnostic markets. Strengthened Financial and Market Outlook: The combination of steady, high-volume public sector contracts alongside higher-margin private retail services significantly reinforces Krsnaa’s financial resilience. This diversified operational approach provides a robust buffer against localized market shifts and sector-specific challenges. Enhanced Healthcare Accessibility and Scale: By capitalizing on both growth engines, Krsnaa effectively bridges regional healthcare gaps. The dual strategy allows the company to simultaneously deliver affordable diagnostic care to mass public markets while offering premium, accessible services to the growing retail healthcare consumer base.

See More

Krsnaa Diagnostics Limited Latest Updates

FY26 Financial Summary For the full financial year 2025-26, the company posted a consolidated revenue from operations of ₹772.77 crore (+7.75% YoY). Backed by solid execution, its annual consolidated net profit rose by 30.7% to ₹101.43 crore, hitting the highest reported profit after tax in the company's history since listing. Rapid Retail Diagnostics Scaling The group's specialized retail vertical (Krsnaa Retail) turned into an independent growth pillar, delivering an 8x vertical surge in revenue to hit ₹60 crore for the fiscal year. The asset-light retail network scaled up rapidly to include more than 3,500 collection touchpoints distributed across 5 core states. Dividend Recommendation Aligning with its formal board approvals filed on May 25, 2026, the company recommended a final dividend of ₹2.00 per equity share (representing 40% of the ₹5 face value) for FY25-26. This distribution remains subject to final shareholder ratification at the company's upcoming Annual General Meeting. Strategic Network Reach The company closed out the fiscal year servicing over 20 million individual patients and processing a total of 59 million tests. Its public-private partnership (PPP) network and private infrastructure expanded to comprise 190 CT/MRI radiology centers, 147 core pathology processing labs, and an expansive pool of over 4,700 processing touchpoints. Q4 FY26 Explosive Profit Surge During the final quarter ended March 31, 2026, operational revenue grew 3.5% year-on-year to ₹192.60 crore. Driven by optimized capacity utilization across regional diagnostic hubs and an embedded fair valuation gain of ₹22.17 crore from its strategic Apulki Healthcare investment, the company’s Q4 net profit doubled (+101.75% YoY) to ₹41.72 crore.

See More

Krsnaa Diagonistics Latest Updates

Major Governance & Leadership Restructuring The company undertook an extensive corporate governance overhaul following its recent board meetings. Effective late April 2026, Krsnaa Diagnostics reconstituted all five of its core board committees under new leadership structures. This structural update included the formal appointments of Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Independent Directors to enhance regulatory oversight. Top Management Transitions The management team has seen significant transitions over the last few months. Mr. Chandra Prakash Singh has been integrated into the executive leadership team as the Interim Chief Financial Officer following the resignation of the long-standing CFO, Mr. Pawan Daga. Additionally, the company processed the departure of its Head of Investor Relations, Mr. Vivek Jain, in late March. Executive Chairman Re-appointment The board approved the re-appointment of Mr. Rajendra Mutha as the Executive Chairman of the company for a consecutive five-year tenure, running from April 26, 2026, to April 25, 2031. The leadership extension was executed following the recommendations of the Nomination and Remuneration Committee and was formalized through a completed postal ballot voting process. ₹430 Crore NCD Allotment to ADB Krsnaa Diagnostics officially closed and finalized the allotment of unlisted, secured Non-Convertible Debentures (NCDs) valued at ₹430 crore. The capital infusion, which was executed on a private placement basis, was formally completed via the company's Operations Committee following strategic investment approvals from the Asian Development Bank (ADB).

See More

Charts Dual Growth Path with PPP and Retail Expansion

, a leading PPP diagnostics player, delivered strong Q2FY26 results with margin expansion despite stretched receivables and retail build-out costs. The company is executing a dual-lever strategy—strengthening its PPP contracts while aggressively scaling its B2C retail footprint—to diversify revenue and sustain long-term growth. The Rajasthan project is progressing well, with 35 labs and 500 collection centres expected by December, and the balance 152 labs and 1,100 centres by Q4FY26. This project could add ₹300–350 crore annually, with meaningful impact from FY27. Maharashtra’s 73 radiology centres are also underway, with 25 MRI sites nearing completion. Revenue grew 11% YoY despite expiry of certain PPP contracts. EBITDA rose 18% with margins at 29%, while PAT increased 22% (12% margin). Margin expansion of ~190 bps was driven by higher radiology utilisation, manpower optimisation, faster supply-chain turnaround, automation, and retail traction. Retail revenue surged 11x YoY to ₹174 million in Q2, now contributing ~8% of H1FY26 revenue versus ~1% last year. The company added 2,800 touchpoints in Maharashtra, Punjab, Assam, and Odisha through an asset-light, partnership-led model. Retail is expected to reach 15–20% of FY27 revenue, with long-term ambition of 40–50%. Transition to the SNA–SPARSH platform extended receivables to ~150 days in Q2. Management aims to reduce this to ~100 days, a key monitorable for investors given the working capital intensity of PPP contracts. Krsnaa is balancing PPP leadership with retail expansion. Retail EBITDA remains negative due to upfront costs but is expected to break even by FY26-end. Management guides for high-teen revenue growth, steady ~29% EBITDA margins, and RoCE improvement to 15%, supported by shared PPP-retail infrastructure and cost leadership.

See More